Magnesium Carbonate: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 29, 2026🚩 Report this page

Magnesium Carbonate

Active ingredient · 2 therapeutic classes

Sold as Humco Dewees Carminative

US FDAGB MHRA

Drug class: Magnesium Compounds
Availability: Over-the-counter
Routes: Oral
Markets covered: 2
Products on record: 2
FDA reports (12 mo): 417

A02AAMagnesium Compounds A06ADOsmotically Acting Laxatives

Overview

Magnesium Carbonate is an active pharmaceutical ingredient in the Magnesium Compounds group (A02AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
US United States	FDA	1	December 15, 2023
GB United Kingdom	MHRA	1	May 29, 2026

USUnited States· FDA

1 product

Uses

USOfficial regulatory label· revised December 15, 2023[1]

Use For the temporary relief of upset stomach or sour stomach, and acid indigestion.

How to take

USOfficial regulatory label

GBUnited Kingdom· MHRA

1 product

Uses

GBOfficial regulatory label· revised May 29, 2026[2]

For the relief of indigestion, heartburn, nervous indigestion, hyperacidity, flatulence, upset stomach, dyspepsia, biliousness, overindulgence in food and drink, indigestion during pregnancy.

How to take

Drug interactions

Known interactions involving Magnesium Carbonate. Select one for details. This list is informational and not a complete interaction checker.

Bictegravir Dolutegravir Erdafitinib Patiromer Raltegravir Selpercatinib Acalabrutinib Acetohexamide Alendronate Amphetamine Amprenavir Aspirin Atazanavir Atropine Azithromycin Bacampicillin Baloxavir Marboxil Benzphetamine Bisacodyl Bosutinib Cabotegravir Calcifediol Calcitriol Cefdinir Cefditoren Cefpodoxime Cefuroxime Ceritinib Chloroquine Chlorpropamide Cholecalciferol Cinoxacin Ciprofloxacin Dabrafenib Dasatinib Deferiprone Delafloxacin Delavirdine Demeclocycline Dextroamphetamine Dihydrotachysterol Doxercalciferol Doxycycline Eltrombopag Elvitegravir Enoxacin Ergocalciferol Erlotinib Ferrous Fumarate Ferrous Gluconate Fexofenadine Gatifloxacin Gemifloxacin Glimepiride Glipizide Glyburide Grepafloxacin Hydroxychloroquine Ibandronate Iron Iron Protein Succinylate Itraconazole Ketoconazole Ledipasvir Levofloxacin Levothyroxine Liothyronine Lisdexamfetamine Lomefloxacin Magnesium Chloride Magnesium Glycinate Magnesium Hydroxide Magnesium Oxide Magnesium Sulfate Methenamine Minocycline Misoprostol Moxifloxacin Mycophenolate Mofetil Mycophenolic Acid Neratinib Nilotinib Norfloxacin Ofloxacin Omadacycline Oxytetracycline Paricalcitol Pazopanib Penicillamine Pexidartinib Phenyl Salicylate Phenytoin Quinidine Rifampin Rilpivirine Riociguat Risedronic Acid Rosuvastatin Salicylic Acid Salsalate Sarecycline Sparfloxacin Tetracycline Tiludronic Acid Tipranavir Tolazamide Tolbutamide Trovafloxacin Velpatasvir Acebutolol Alprazolam Atenolol Axitinib Benazepril Betaxolol Bisoprolol Capecitabine Captopril Carteolol Carvedilol Chlordiazepoxide Chlorpromazine Cimetidine Clobazam Clonazepam Clorazepate Diazepam Digitoxin Digoxin Duloxetine Enalapril Erythromycin Estazolam Famotidine Fluphenazine Flurazepam Fosinopril Gabapentin Halazepam Indomethacin Labetalol Lactulose Levodopa Lisinopril Lorazepam Mefenamate Mesoridazine Methdilazine Methotrimeprazine Metoprolol Midazolam Moexipril Nadolol Naproxen Nebivolol Nitrofurantoin Nizatidine Oxazepam Penbutolol Perindopril Perphenazine Pindolol Ponatinib Prochlorperazine Promazine Promethazine Propiomazine Propranolol Quazepam Quinapril Ramipril Ranitidine Sotalol Tacrolimus Temazepam Thiethylperazine Thioridazine Ticlopidine Timolol Trandolapril Triazolam Trifluoperazine Triflupromazine Trimeprazine Valproate Vismodegib Zalcitabine

Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.

Sources & citations

[1]FDA DailyMed · 163bceeb-ca74-41… · revised December 15, 2023 [PDF]
[2]MHRA (UK) · PL434610127 · revised May 29, 2026
[3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised May 29, 2026[2]

The listed adverse drug reactions are based on spontaneous reports, thus an organisation according to CIOMS III categories of frequency is not possible.
Immune System Disorders:
Hypersensitivity reactions have very rarely been reported. Clinical symptoms may include rash, urticaria, pruritus, angioedema, difficulty in breathing and anaphylaxis.
Metabolism and Nutrition Disorders:
Especially in patients with impaired renal function, prolonged use of high doses can result in hypermagnesaemia or hypercalcaemia and alkalosis which may give rise to gastric symptoms and muscular weakness (see below).
Gastrointestinal Disorders:
Nausea, vomiting, stomach discomfort, constipation and diarrhoea may occur.
Musculoskeletal and Connective Tissue Disorders:
Muscular weakness may occur. 9) Gastrointestinal Disorders: Ageusia may occur in the context of milk-alkali syndrome.
General Disorders and Administration Site Conditions:
Calcinosis and asthenia may occur in the context of milk-alkali syndrome.
Nervous System Disorders:
Headache may occur in the context of milk-alkali syndrome.
Renal and Urinary Disorders:
Azotemia may occur in the context of milk-alkali syndrome. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised May 29, 2026[2]

• Prolonged use should be avoided. • The stated dose should not be exceeded. If, after 14 days of treatment, symptoms persist or only partly disappear the patient should consult a doctor. 3 – contraindication in severe renal insufficiency).
If Flamingo Indigestion Relief Peppermint chewable tablets is used in such patients, plasma calcium, phosphate and magnesium levels should be regularly monitored. • Long term uses at high doses can result in undesirable effects such as hypercalcaemia, hypermagnesaemia and milk-alkali syndrome, especially in patients with renal insufficiency.
3). Prolonged use increases the risk of formation of renal calculi. • This product should not be taken with large amounts of milk or dairy products. This medicine contains sucrose. Patients with rare hereditary problems of fructose intolerance, glucose galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
This medicine contains less than 1 mmol (23mg) sodium per tablet, that is to say essentially ‘sodium-free’.

This is not medical advice. Consult a qualified healthcare professional.